Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2017-03-13 Regulatory Filings
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing, which is a current report filed with the SEC to announce major events that shareholders should know about. The text describes a meeting with the FDA regarding clinical trial development plans and modifications to the statistical analysis plan for a Phase 2b/3 clinical trial. It does not contain financial statements or detailed financial data, nor is it an earnings release or annual/interim report. The document is an announcement of a significant event related to regulatory and clinical development progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. The document length is under 5,000 characters and it is not a report publication announcement or certification. Hence, the classification is RNS with high confidence.
2017-03-13 English
PRIMARY DOCUMENT
Director's Dealing
2017-02-28 English
Earnings Release 2017
Earnings Release Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the quarter and full year ending December 31, 2016. The press release is furnished as an exhibit and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3688 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the rules, if a document is short and primarily announces or furnishes a press release with financial results, it should be classified as an Earnings Release (ER) if it contains key highlights or as Regulatory Filings (RNS) if it is just an announcement. However, since the document states it is furnishing a press release announcing quarterly and full year financial results and provides a business update, this aligns with the definition of an Earnings Release (ER). Therefore, the classification is ER with high confidence.
2017-02-27 English
Annual Report 2016
Annual Report FY 2016
2017-02-27 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-15 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.